Telix Pharmaceuticals (ASX:TLX) set to rake in $175m from placement
Telix Pharmaceuticals (TLX) announces successful $175 million institutional placement which it says…
Telix Pharmaceuticals Limited (ASX:TLX)
$6.58
-0.61 (-8.48%)
MCAP $2.049B
Last trade
15.24pm 25/01/2022
20mins delayed
Latest Announcements
24/01/2022TLXTelix Pharmaceuticals Limited
192
MCap
24/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
24/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
271
MCap
24/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
20/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
12,439
MCap
11/01/2022TLXTelix Pharmaceuticals Limited
21/12/2021TLXTelix Pharmaceuticals Limited
21/12/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
Company Overview
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The Company's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.
